Gelteq Limited GELS 深 滬
等待開盤 01-13 09:30:00 美东时间
0.7851
-0.046
-5.56%
華盛通- 最 高0.8515
- 今 開0.8269
- 成交量 2.46万股
- 最 低 0.7851
- 昨 收 0.8313
- 總市值 787.30万
- 52周最高 4.11
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.7701
- 委 比 -50.00%
- 總股本 1002.80万
- 歷史最高 5.50
- 量 比 4.88
- 振 幅 7.99%
- 歷史最低 0.7701
- 每 手 1
- 風險率 0.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Gelteq Signs 3-Year China Distribution Deal With Mana To Expand Nutritional Product Portfolio; Expects To Derive A Minimum Revenue Of ~$1.3M During The Term Of The Agreement
Gelteq Limited ("Gelteq" or the "Company"), a clinical and science based innovator in gel based oral delivery technologies, today announced that it has entered into a three year sales agreement with Shenzhen Mana Health
2025-12-09 22:16
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers GT Biopharma (NASDAQ:GTBP) shares moved upwards by 6.6% to $0.65 durin...
2025-12-06 05:05
Gelteq Announces Preclinical Results Showing That Its Proprietary Gel-Based Oral Delivery Formulation Significantly Improves The Bioavailability Of An Antihistamine Compared To A Leading Existing Product
Gelteq Limited ("Gelteq" or the "Company"), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced positive preclinical results showing its proprietary gel formulation
2025-11-24 21:34
Gelteq Announces Start Of A Preclinical Animal Trial With Monash University To Evaluate Its Proprietary Gel-Based Oral Delivery Technology For Oily And Poorly Soluble Drugs
Gelteq Limited ("Gelteq" or the "Company"), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced it has started a preclinical animal trial evaluating its proprietary
2025-10-23 21:06
Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform
Gelteq Limited has commenced a preclinical animal trial with Monash University to evaluate its proprietary gel-based technology for improving the oral delivery of oily and poorly soluble drugs, addressing a major challenge in pharmaceutical development. Over 40% of marketed drugs and 90% of discovery candidates face solubility issues, leading to inconsistent outcomes. Gelteq aims to assist pharmaceutical partners through pipeline salvage, lifecyc...
2025-10-23 13:00
Gelteq Signs Product Development, Profit Share Agreement With Melbourne Health To Develop New Products Incorporating High-amylose Maize Starch Butyrylated
MELBOURNE, Australia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company"), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced it has entered
2025-10-09 20:11
Gelteq Announces New Product Development Agreement with Melbourne Health for Novel Bowel Polyp Growth Reduction Compound
Melbourne, Australia, October 9, 2025 – Gelteq Limited has signed a Product Development and Profit Share Agreement with Melbourne Health to develop a new product containing HAMSB (high-amylose maize starch butyrylated), a compound showing potential to reduce bowel polyp growth and lower bowel cancer risk. HAMSB, a modified starch, has been extensively researched by Melbourne Health and CSIRO, with a recent study highlighting its significant impac...
2025-10-09 12:00
Gelteq Technology Powers U.S. Product Launches of its Nutraceutical Products for Partner
Gelteq Limited welcomed Healthy Extracts, Inc.'s product launches using Gelteq's proprietary gel technology into the U.S. nutraceutical market. These products marked Gelteq's transition from R&D to commercialization in the U.S., highlighting the technology's growth potential and ability to meet consumer demand. Gelteq's CEO, Nathan Givoni, expressed excitement about the collaboration, emphasizing the adaptability of their gels and the potential f...
2025-09-12 11:30
Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market
Gelteq Limited plans to initiate a preclinical bioequivalence study in September 2025 for its novel gel-based antihistamine formulation, aiming to seek FDA approval via the 505(b)(2) pathway. If successful, the study will lead to human clinical trials. The gel-based delivery platform addresses key challenges such as patient compliance, precise dosing, and palatability, particularly in paediatrics and veterinary care. With a global antihistamine m...
2025-09-05 15:26
Gelteq And Healthy Extracts Launch Hydrate EZ And Mynus Sugar Gel-Packs With Innovative No-Mix Delivery Technology
Hydrate EZ™ delivers rapid hydration and essential electrolytes for staying refreshed, sharp and in control.Mynus Sugar™ is clinically formulated to support healthy carbohydrate metabolism.Both products
2025-09-04 20:43
